Quest Diagnostics (DGX)

• Market cap: $19.1B
• 1 day: 0.06%
• 5 days: 1.77%
• 1 month: 12.83%
• 3 months: 5.09%
• 6 months: 12.60%
• Year to date: 14.10%
• 1 year: 35.91%
• 5 years: 52.22%
• 10 years: 142.63%
• Sector: Healthcare
• Industry: Medical Laboratories

About: Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the us. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.

Employees: 48,000

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

91% more first-time investments, than exits

New positions opened: 111 | Existing positions closed: 58

81% more call options, than puts

Call options by funds: $63.1M | Put options by funds: $35M

2% more funds holding

Funds holding: 832 [Q3] → 852 (+20) [Q4]

6% more repeat investments, than reductions

Existing positions increased: 302 | Existing positions reduced: 285

0.08% more ownership

Funds ownership: 88.04% [Q3] → 88.11% (+0.08%) [Q4]

2% less capital invested

Capital invested by funds: $15.1B [Q3] → $14.8B (-$299M) [Q4]

50% less funds holding in top 10

Funds holding in top 10: 2 [Q3] → 1 (-1) [Q4]

Research analyst outlook

10 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $170 1% downside
• Avg. target: $178 3% upside
• High target: $185 7% upside

10 analyst ratings

• positive: 5 50%
• neutral: 5 50%
• negative: 0 0%

JP Morgan Lisa Gill 57% 1-year accuracy 13 / 23 met price target	5% upside $180	Neutral Maintained	4 Feb 2025
Mizuho Ann Hynes 61% 1-year accuracy 11 / 18 met price target	3% upside $178	Outperform Maintained	3 Feb 2025
UBS Kevin Caliendo 50% 1-year accuracy 8 / 16 met price target	1% downside $170	Neutral Maintained	3 Feb 2025
Piper Sandler David Westenberg 51% 1-year accuracy 21 / 41 met price target	5% upside $180	Neutral Reiterated	3 Feb 2025
Truist Securities David Macdonald 59% 1-year accuracy 57 / 96 met price target	6% upside $182	Hold Maintained	31 Jan 2025